GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Santen Pharmaceutical Co Ltd (TSE:4536) » Definitions » Cyclically Adjusted Revenue per Share

Santen Pharmaceutical Co (TSE:4536) Cyclically Adjusted Revenue per Share : 円629.83 (As of Mar. 2024)


View and export this data going back to 1964. Start your Free Trial

What is Santen Pharmaceutical Co Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Santen Pharmaceutical Co's adjusted revenue per share for the three months ended in Mar. 2024 was 円217.088. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is 円629.83 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Santen Pharmaceutical Co's average Cyclically Adjusted Revenue Growth Rate was 10.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 10.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 9.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Santen Pharmaceutical Co was 10.50% per year. The lowest was 8.40% per year. And the median was 9.15% per year.

As of today (2024-06-07), Santen Pharmaceutical Co's current stock price is 円1628.00. Santen Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was 円629.83. Santen Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is 2.58.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Santen Pharmaceutical Co was 5.62. The lowest was 1.77. And the median was 3.62.


Santen Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Santen Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santen Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Santen Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 433.74 467.24 511.91 570.54 629.83

Santen Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 570.54 585.05 601.51 615.91 629.83

Competitive Comparison of Santen Pharmaceutical Co's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - General subindustry, Santen Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Santen Pharmaceutical Co's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Santen Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Santen Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.



Santen Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Santen Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=217.088/107.2000*107.2000
=217.088

Current CPI (Mar. 2024) = 107.2000.

Santen Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 81.300 98.000 88.932
201409 92.186 98.500 100.328
201412 108.158 97.900 118.432
201503 108.421 97.900 118.720
201506 115.481 98.400 125.809
201509 120.057 98.500 130.661
201512 123.470 98.100 134.923
201603 110.838 97.900 121.367
201606 120.275 98.100 131.432
201609 115.158 98.000 125.969
201612 129.256 98.400 140.815
201703 118.781 98.100 129.799
201706 137.248 98.500 149.370
201709 134.447 98.800 145.878
201712 141.718 99.400 152.839
201803 138.090 99.200 149.226
201806 138.396 99.200 149.557
201809 141.744 99.900 152.102
201812 144.167 99.700 155.012
201903 150.190 99.700 161.488
201906 147.762 99.800 158.718
201909 148.984 100.100 159.551
201912 158.728 100.500 169.310
202003 148.029 100.300 158.212
202006 143.780 99.900 154.286
202009 153.196 99.900 164.391
202012 157.034 99.300 169.527
202103 169.391 99.900 181.769
202106 162.332 99.500 174.894
202109 159.241 100.100 170.536
202112 167.381 100.100 179.253
202203 175.918 101.100 186.532
202206 164.943 101.800 173.692
202209 166.851 103.100 173.486
202212 183.341 104.100 188.801
202303 209.904 104.400 215.534
202306 193.565 105.200 197.245
202309 203.044 106.200 204.956
202312 217.026 106.800 217.839
202403 217.088 107.200 217.088

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Santen Pharmaceutical Co  (TSE:4536) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Santen Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1628.00/629.83
=2.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Santen Pharmaceutical Co was 5.62. The lowest was 1.77. And the median was 3.62.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Santen Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Santen Pharmaceutical Co's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Santen Pharmaceutical Co (TSE:4536) Business Description

Traded in Other Exchanges
Address
Grand Front Osaka Tower A, 4-20 Ofuka-cho, Kita-ku, Osaka, JPN, 530-8552
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company reports two primary operating segments: prescription ophthalmic pharmaceuticals and other. The pharmaceuticals segment includes over-the-counter pharmaceuticals, while the other segment includes medical devices. The vast majority of Santen's revenue is derived from its prescription ophthalmic pharmaceuticals segment, which manufactures and distributes prescription and OTC pharmaceuticals. Most of Santen's sales are generated in Japan, followed by other Asian countries.

Santen Pharmaceutical Co (TSE:4536) Headlines

No Headlines